Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -42.72% is 21% above its 5-year average of -54.35%, near the high end of its 5-year range (-284.85%–-4.23%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.17% above its 12-month average of -62.98%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -42.72%.
RETURN ON EQUITY (ROE)
-42.72%
RETURN ON EQUITY (ROE) AVG TTM
-62.98%
RETURN ON EQUITY (ROE) AVG 3Y
-73.70%
RETURN ON EQUITY (ROE) AVG 5Y
-54.35%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.17%
CURRENT VS 3Y AVG
+42.03%
CURRENT VS 5Y AVG
+21.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-1.69%
vs the sector median at left
Pasithea Therapeutics Corp.
Market Cap
$14.94M
Return on Equity (ROE)
-42.72%
TTM Avg
-62.98%
3Y Avg
-73.70%
5Y Avg
-54.35%
Market Cap
$14.73M
Return on Equity (ROE)
N/A
TTM Avg
54.00%
3Y Avg
301.36%
5Y Avg
162.15%
Market Cap
$15.30M
Return on Equity (ROE)
-951.92%
TTM Avg
-161.65%
3Y Avg
-122.41%
5Y Avg
-87.71%
Market Cap
$14.46M
Return on Equity (ROE)
-186.95%
TTM Avg
1198.98%
3Y Avg
241.18%
5Y Avg
112.17%
Market Cap
$15.58M
Return on Equity (ROE)
4.02%
TTM Avg
8.39%
3Y Avg
11.64%
5Y Avg
14.29%
Market Cap
$15.68M
Return on Equity (ROE)
-348.81%
TTM Avg
-160.92%
3Y Avg
-184.71%
5Y Avg
-151.29%
Market Cap
$15.78M
Return on Equity (ROE)
-271.81%
TTM Avg
-934.34%
3Y Avg
-347.56%
5Y Avg
-265.02%
Market Cap
$14.05M
Return on Equity (ROE)
-19.08%
TTM Avg
-28.50%
3Y Avg
-28.27%
5Y Avg
-100.79%
Market Cap
$13.86M
Return on Equity (ROE)
-372.67%
TTM Avg
-433.17%
3Y Avg
-292.89%
5Y Avg
-208.82%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $14.94M | -42.72% | -62.98% | -73.70% | -54.35% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | N/A | 54.00% | 301.36% | 162.15% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -951.92% | -161.65% | -122.41% | -87.71% |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | -186.95% | 1198.98% | 241.18% | 112.17% |
| Jin Medical International Ltd. (ZJYL)vs › | $15.58M | 4.02% | 8.39% | 11.64% | 14.29% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | -348.81% | -160.92% | -184.71% | -151.29% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | -271.81% | -934.34% | -347.56% | -265.02% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.05M | -19.08% | -28.50% | -28.27% | -100.79% |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -372.67% | -433.17% | -292.89% | -208.82% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
ROE
-42.7%
ROA
-41.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -42.72% |
| 2026-03-31 | -36.00% |
| 2025-12-31 | -36.99% |
| 2025-09-30 | -110.55% |
| 2025-06-30 | -88.66% |
| 2025-03-31 | -104.84% |
| 2024-12-31 | -94.06% |
| 2024-09-30 | -88.56% |
| 2024-06-30 | -101.31% |
| 2024-03-31 | -81.90% |
| 2023-12-31 | -68.22% |
| 2023-09-30 | -56.50% |
| 2023-06-30 | -47.78% |
| 2023-03-31 | -40.63% |
| 2022-12-31 | -32.79% |
| 2022-09-30 | -17.50% |
| 2022-06-30 | -9.96% |
| 2022-03-31 | -6.40% |
| 2021-12-31 | -4.23% |
| 2021-09-30 | -17.31% |
| 2021-06-30 | -284.85% |
